OncoMatch/Clinical Trials/NCT07647328
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Is NCT07647328 recruiting? Yes, currently enrolling (Jul 2026). This Phase 3 trial studies multiple treatments including Camizestrant and Ribociclib for er-positive her2-negative breast cancer.
Treatment: Camizestrant · Ribociclib — The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 expression (positive)
ER+
Required: HER2 (ERBB2) wild-type (negative)
HER2-
Disease stage
Required: Stage STAGE 4
not amenable to resection or radiation therapy with curative intent; de novo Stage 4 disease, or recurrence from early CD stage breast cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1
Demographics
Prior therapy
Lab requirements
Blood counts
Adequate organ and marrow function
Kidney function
Adequate organ and marrow function
Liver function
Adequate organ and marrow function
Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Palo Alto, California
- Research Site · Marietta, Georgia
- Research Site · Evanston, Illinois
- Research Site · Edgewood, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07647328 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage STAGE 4 is required.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages